Centessa Pharmaceuticals plc - ADR Forecast, price target & analysts
Centessa Pharmaceuticals plc - ADR Target price 2025 - Analyst rating & recommendation
Centessa Pharmaceuticals plc - ADR Classifications & Recommendation:
Centessa Pharmaceuticals plc - ADR Price Target
| Target Price | $36.72 |
| Price | $25.68 |
| Potential |
42.99%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Centessa Pharmaceuticals plc - ADR 2026 .
The average Centessa Pharmaceuticals plc - ADR target price is $36.72.
This is
42.99%
register free of charge
$54.60
112.62%
register free of charge
$30.30
17.99%
register free of charge
|
|
| A rating was issued by 21 analysts: 20 Analysts recommend Centessa Pharmaceuticals plc - ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Centessa Pharmaceuticals plc - ADR stock has an average upside potential 2026 of
42.99%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 16.08 |
| 100.00% |
17 Analysts have issued a sales forecast Centessa Pharmaceuticals plc - ADR 2025 . The average Centessa Pharmaceuticals plc - ADR sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Centessa Pharmaceuticals plc - ADR EBITDA forecast 2025. The average Centessa Pharmaceuticals plc - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
17 Centessa Pharmaceuticals plc - ADR Analysts have issued a net profit forecast 2025. The average Centessa Pharmaceuticals plc - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.06 | -1.41 |
| 31.21% | 31.55% | |
| P/E | negative | |
| EV/Sales | 202.65 |
17 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast for earnings per share. The average Centessa Pharmaceuticals plc - ADR EPS is
This results in the following potential growth metrics and future valuations:
Centessa Pharmaceuticals plc - ADR...
Current Centessa Pharmaceuticals plc - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Dec 01 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Nov 18 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Oct 28 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Oct 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Dec 01 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Nov 18 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Oct 28 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Oct 06 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
